HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors.
The proceeds will fund the commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and general corporate purposes. This capital infusion positions the company to accelerate the rollout of its innovative cardiac monitoring platform, which has received significant regulatory milestones.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. The HeartBeam System is designed to be the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring.
According to the company, this platform technology allows physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care outside of a medical facility. The funding will support the company's mission to redefine cardiac health management through actionable heart intelligence delivered wherever the patient is.
For more details on the offering, the full press release is available at https://ibn.fm/9iNYY. Additional information about HeartBeam and its technology can be found on the company's website, including cleared indications for use at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
